Long-Term Debt: Molecular Templates Corp (MTEM)

Brandmark of Molecular Templates Corporation (MTEM)

Molecular Templates develops innovative medicines based on plant toxins to combat resistant tumors. Business growth relies on the development of the ETB platform, the success of which depends on grants and partnerships with pharma behemoths. The current figure is 0.01. The confirmed price history on this chart underscores the asset's speculative status amid a severe shortage of funds and the reduction of several programs.

MTEM (Molecular Templates Corp) Company Long-Term Debt history from 07/04/2022 to 12/28/2024

Molecular Templates Corp - analytical breakdowns and key metrics (MTEM)

- current quotes and average value forecast:
Stock Quotes mtem.com|MTEM - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Molecular Templates|MTEM - Total Company Value
- book capitalization data:
Net Assets per Single Share Molecular Templates|MTEM - Company Book Value|Market-to-Book Ratio mtem.com|MTEM - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Molecular Templates|MTEM - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Molecular Templates Corporation|MTEM - Company Total Debt|Debt to Net Assets Ratio Molecular Templates|MTEM - Company Long-Term Debt|Current Liabilities Molecular Templates
Fundamental company valuation:mtem.com
Core merchandise of Molecular Templates, Inc.

The reliability of Molecular Templates (MTEM) for long-term capital is currently raising serious concerns. This metric captures the total volume of liabilities with a maturity of more than one year, reflecting the actual burden of borrowed capital. By analyzing the corporation's long-term debt, an investor assesses the balance between expansion and solvency. Amid the closure of clinical programs, an increase in this indicator signals a critical liquidity shortage. The current debt load confirms extreme liquidation risks for the startup.

Competitors of Molecular Templates (MTEM)

GERN - Company Long-Term Liabilities|NBTX - Company Long-Term Debt|Long-Term Debt Bicycle Therapeutics PLC|CytomX Therapeutics Inc (CTMX) - Company Long-Term Debt|CATX (Perspective Therapeutics, Inc.) - Company Long-Term Debt|Company Long-Term Debt Genelux Corp.|Long-Term Debt Molecular Partners Ltd MOLN|Company Long-Term Debts ONCY|lisata.com (LSTA) - Long-Term Indebtedness|Moleculin Biotech - Company Long-Term Liabilities|Galera Therapeutics Inc. (GRTX) - Long-Term Debt